Manufacturing & Quality Blueprint
Adverse event volumes keep rising as products reach more markets and more patients, and regulators expect faster signal detection than manual case review can deliver. The Adverse Event Signals Agent continuously analyzes case reports, literature, and post-market data to surface emerging safety signals before they escalate.
Designed for
Talk to us
Why now
Case volumes have outgrown manual review capacity, and regulators now expect signal detection measured in days, not review cycles. Continuous, automated screening is becoming the baseline pharmacovigilance teams are held to.
Measured against signal outcomes
Catching a safety signal isn't just about compliance — it's about protecting patients the moment a pattern emerges. The Adverse Event Signals Agent delivers measurable improvement across the pharmacovigilance lifecycle.
70
%
faster identification of emerging safety signals
55
%
reduction in manual case review effort
45
%
improvement in signal-to-escalation time
35
%
improvement in pharmacovigilance team throughput
What changes for your safety team
By continuously scanning case reports and post-market data, pharmacovigilance organizations catch emerging signals earlier and escalate with stronger evidence.
Continuously scan case reports, literature, and post-market data to flag emerging safety patterns before they escalate.
Faster escalation decisions
Surface the specific reports and trends behind a signal so safety teams can assess and escalate with confidence, not delay.
Better use of PV team time
Free pharmacovigilance reviewers from manual case triage so they can focus on genuine signal assessment and escalation.
Stronger regulatory confidence
Maintain a clear, traceable record of every signal and its supporting evidence, ready for regulatory reporting and inspection.
Smarter Workspace
